Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2025 | $20.00 | Hold → Buy | D. Boral Capital |
| 11/1/2021 | $4.00 | Buy | HC Wainwright & Co. |
3 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
DEF 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00
HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00
LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy
SOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the publication of new peer-reviewed research from the laboratory of Dr. Steven Laviolette, Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, partially funded by the Company, demonstrating that intraperitoneal administration of Artelo's proprietary FABP5 inhibitor SBFI103 produces robust anxiolytic and antidepressant-like eff
SOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended September 30, 2025. "We continue to deliver on our clinical and strategic objectives, advancing three differentiated programs with strong potential to address large, underserved markets," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "We were very pleased with
SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, "The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers", in Drug Discovery Today. The publication's lead author is Dr. George Warren, Principal Scientist at Artelo. This publication marks the third in a trilogy of reviews exploring the protumoral roles of FABP isoforms 3, 5, and 7 in cancer biology. This publication underscores growing evid
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthens Artelo's financial leadership as it advances its clinical pipeline and corporate growth initiatives. Mark Spring brings 30 years of experience in life sciences to his role, including f
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)